Best case scenario (best 10 out of 100 similar women) would be progression free for months on placebo and months on olaparib
Typical range (middle 50 of 100 similar women) would be progression-free somewhere between months on placebo, and months on olaparib
Worst case scenario (worst 10 of 100 similar) women would be progression-free for months on placebo and months on olaparib.